{
    "clinical_study": {
        "@rank": "112628", 
        "arm_group": [
            {
                "arm_group_label": "Gluteal Injection", 
                "arm_group_type": "Other"
            }, 
            {
                "arm_group_label": "Deltoid Injection", 
                "arm_group_type": "Other"
            }
        ], 
        "brief_summary": {
            "textblock": "To determine the safety and tolerability of multiple-dose administrations of aripiprazole\n      intramuscular (IM) depot in the deltoid muscle in adult subjects with schizophrenia"
        }, 
        "brief_title": "Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Schizophrenia", 
            "Mental Disorder", 
            "Nervous System Diseases"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Mental Disorders", 
                "Psychotic Disorders", 
                "Nervous System Diseases", 
                "Schizophrenia"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a trial designed to assess the safety and tolerability of multiple-dose\n      administrations of aripiprazole intramuscular (IM) depot in the deltoid muscle in adult\n      subjects with schizophrenia. The trial consists of a 113 day treatment period with a 28 day\n      followup. The trial population will include male and female subjects between 18 and 64 years\n      (inclusive), with a current diagnosis of schizophrenia as defined by DSM-IV-TR criteria and\n      a prior history of tolerating aripiprazole per investigator's judgement."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female individuals between 18 and 64 years, inclusive, at the time of\n             informed consent.\n\n          -  Prior history of tolerating aripiprazole per investigator's judgement.\n\n        Exclusion Criteria:\n\n          -  Subjects who have met DSMV-IV-TR criteria for substance dependence within the past\n             180 days.\n\n          -  Subjects who use more than one antipsychotic medication at screening.\n\n          -  Use of any CYP2D6 and CYP3A4 inhibitors, or CYP3A4 inducers within 14 days prior to\n             dosing and for the duration of the trial.\n\n          -  Subjects who participated in any clinical trial involving a psychotropic medication\n             within 1 month prior to enrollment.\n\n          -  Subjects currently in an acute relapse of schizophrenia.\n\n          -  Subjects with a current DSMV-IV-TR diagnosis other than schizophrenia.\n\n          -  Subjects who are considered treatment-resistant to antipsychotic medications."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "141", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01909466", 
            "org_study_id": "31-12-298"
        }, 
        "intervention": {
            "arm_group_label": [
                "Gluteal Injection", 
                "Deltoid Injection"
            ], 
            "description": "5 monthly applications of 400 mg of aripiprazole IM depot, where the first application is in the gluteal or deltoid muscle followed by 4 monthly administrations to the deltoid muscle", 
            "intervention_name": "Aripiprazole, OPC-14597", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Aripiprazole"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "OPC-14597", 
            "Aripiprazole", 
            "Schizophrenia"
        ], 
        "lastchanged_date": "April 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Cerritos", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90703"
                    }, 
                    "name": "Comprehensive Clinical Development"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Garden Grove", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92845"
                    }, 
                    "name": "Collaborative Neuroscience Network, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92101"
                    }, 
                    "name": "CNRI-San Diego"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20016"
                    }, 
                    "name": "Comprehensive Clinical Development"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ft. Lauderdale", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33308"
                    }, 
                    "name": "Scientific Clinical Research, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leesburg", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34748"
                    }, 
                    "name": "Compass Research North, LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30308"
                    }, 
                    "name": "Atlanta Center for Medical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63118"
                    }, 
                    "name": "St. Louis Clinical Trials"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marlton", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08053"
                    }, 
                    "name": "CRI Lifetree"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19139"
                    }, 
                    "name": "CRI Lifetree"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78754"
                    }, 
                    "name": "Community Clinical Research, Inc."
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-label, Multiple Dose, Safety and Tolerability Study of Aripiprazole IM Depot Administered in the Deltoid Muscle in Adult Subjects With Schizophrenia", 
        "overall_official": {
            "affiliation": "Otsuka Pharmaceutical Development & Commercialization, Inc.", 
            "last_name": "Kimberly Largay, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Safety and tolerability based on reported AEs, laboratory assessments (serum chemistry, hematology, urinalysis), and physical examinations", 
            "safety_issue": "Yes", 
            "time_frame": "113 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01909466"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Safety and tolerability based on visual analog scale (VAS) scores for pain perception, extrapyramidal symptoms, and suicidality via the Columbia-Suicide Severity Rating Scale (C-SSRS)", 
            "safety_issue": "Yes", 
            "time_frame": "113 days"
        }, 
        "source": "Otsuka Pharmaceutical Development & Commercialization, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "H. Lundbeck A/S", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Otsuka Pharmaceutical Development & Commercialization, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}